OnePeptideShip

5-Amino-1MQ Research Profile

Research Use

5-Amino-1MQ is a small, membrane-permeable NNMT (nicotinamide N-methyltransferase) inhibitor. By blocking NNMT, it restores cellular NAD+ levels, shrinks white adipocyte size, and raises basal metabolic rate without appetite suppression.

5-Amino-1MQ Quick Technical Specifications

Category
Metabolism & Fat Burning
Elimination Half-Life
approx. 2 to 6 hours
Storage Protocol
Refrigerated (2°C-8°C)
Status
Research Use
OE
Written by OnePeptideShip Editorial Team
Reviewed by Dr. Aris Thorne, MD, Board Certified Endocrinology Advisor
Updated September 2026

Mechanism of Action & Biochemical Context

5-Amino-1MQ is a small, membrane-permeable NNMT (nicotinamide N-methyltransferase) inhibitor. By blocking NNMT, it restores cellular NAD+ levels, shrinks white adipocyte size, and raises basal metabolic rate without appetite suppression.

Storage, Reconstitution & Stability Guidelines

Prior to reconstitution, lyophilized 5-Amino-1MQ powder should be stored away from light between 2°C and 8°C for short-term access, or -20°C for long-term preservation. Once reconstituted with Bacteriostatic Water (0.9% benzyl alcohol preservative), maintain strict refrigeration between 2°C and 8°C. Do not freeze liquid solution.

Cited Scientific References

  1. Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and enhances performance in aged mice. Biochem Pharmacol. 2019.

Calculate 5-Amino-1MQ Syringe Units

Input your vial mg and BAC water mL to calculate exact U-100 draw units.

Open 5-Amino-1MQ Calculator →

Frequently Asked Questions

Using a 50mg vial with 2mL of BAC water (25mg/mL): 5mg = 0.2mL = 20 units on a U-100 syringe. For a 10mg dose, draw 0.4mL = 40 units.

NNMT (Nicotinamide N-methyltransferase) is an enzyme that consumes NAD+ precursors to methylate nicotinamide. In obese subjects, NNMT is chronically overactivated in fat cells, draining the cellular NAD+ pool and contributing to the metabolic dysfunction that makes obesity hard to reverse. By inhibiting NNMT, 5-Amino-1MQ restores NAD+ levels naturally, activates AMPK and SIRT1 (both longevity/metabolism enzymes), and directly reduces the lipid content of adipocytes.

They work by different mechanisms. NMN and NR are NAD+ precursors - they supply the raw material to make NAD+. 5-Amino-1MQ prevents NAD+ from being wasted by NNMT - it's like plugging a drain instead of running more water. In research, 5-Amino-1MQ can be more effective than NMN/NR alone because it prevents the system from destroying the NAD+ that's already there. Many researchers stack all three.

GLP-1 drugs (Semaglutide, Tirzepatide) work in the brain - they suppress appetite so you eat less. 5-Amino-1MQ works directly in the fat cells and mitochondria - it forces the body to burn fat more efficiently and raises the basal metabolic rate. It does NOT suppress appetite. This makes the two mechanisms highly complementary: GLP-1s create the caloric deficit, while 5-Amino-1MQ ensures that deficit comes primarily from fat rather than muscle or metabolic slowdown.

Yes. Research in animal models showed that NNMT inhibition not only reduced fat mass but also promoted muscle stem cell (satellite cell) proliferation, suggesting a muscle-preserving and even muscle-building effect. This is a major differentiator from GLP-1 drugs, which can cause significant muscle catabolism in large caloric deficits.

Injectable form has significantly higher bioavailability because it bypasses first-pass metabolism in the liver. A 5-10mg injectable dose is typically equivalent in effect to a 50-75mg oral capsule dose, making injectable form far more dose-efficient. However, oral is much more convenient and comfortable. Research is ongoing to establish definitive bioavailability comparisons in humans.

Most injectable research protocols run 8 to 12 weeks, with 1-3 injections per week depending on dosing frequency. Because it is not a hormone or receptor agonist, there is no evidence of receptor desensitization, meaning extended cycles may be feasible. However, prudent research practice includes periodic blood work to monitor liver enzymes and NAD+ metabolites.